<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d343" origId="Imatinib"><sentence id="DrugDDI.d343.s0" origId="s0" text="Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin)."><entity id="DrugDDI.d343.s0.e0" origId="s0.p0" charOffset="0-5" type="drug" text="Drugs"/><entity id="DrugDDI.d343.s0.e1" origId="s0.p4" charOffset="21-29" type="drug" text="imatinib"/><entity id="DrugDDI.d343.s0.e2" origId="s0.p8" charOffset="76-84" type="drug" text="imatinib"/><entity id="DrugDDI.d343.s0.e3" origId="s0.p14" charOffset="150-157" type="drug" text="Gleevec"/><entity id="DrugDDI.d343.s0.e4" origId="s0.p16" charOffset="181-187" type="drug" text="CYP3A4"/><entity id="DrugDDI.d343.s0.e5" origId="s0.p19" charOffset="202-214" type="drug" text="ketoconazole"/><entity id="DrugDDI.d343.s0.e6" origId="s0.p20" charOffset="216-228" type="drug" text="itraconazole"/><entity id="DrugDDI.d343.s0.e7" origId="s0.p21" charOffset="230-242" type="drug" text="erythromycin"/><entity id="DrugDDI.d343.s0.e8" origId="s0.p22" charOffset="244-258" type="drug" text="clarithromycin"/><pair id="DrugDDI.d343.s0.p0" e1="DrugDDI.d343.s0.e0" e2="DrugDDI.d343.s0.e1" interaction="false"/><pair id="DrugDDI.d343.s0.p1" e1="DrugDDI.d343.s0.e0" e2="DrugDDI.d343.s0.e2" interaction="false"/><pair id="DrugDDI.d343.s0.p2" e1="DrugDDI.d343.s0.e0" e2="DrugDDI.d343.s0.e3" interaction="false"/><pair id="DrugDDI.d343.s0.p3" e1="DrugDDI.d343.s0.e0" e2="DrugDDI.d343.s0.e4" interaction="false"/><pair id="DrugDDI.d343.s0.p4" e1="DrugDDI.d343.s0.e0" e2="DrugDDI.d343.s0.e5" interaction="false"/><pair id="DrugDDI.d343.s0.p5" e1="DrugDDI.d343.s0.e0" e2="DrugDDI.d343.s0.e6" interaction="false"/><pair id="DrugDDI.d343.s0.p6" e1="DrugDDI.d343.s0.e0" e2="DrugDDI.d343.s0.e7" interaction="false"/><pair id="DrugDDI.d343.s0.p7" e1="DrugDDI.d343.s0.e0" e2="DrugDDI.d343.s0.e8" interaction="false"/><pair id="DrugDDI.d343.s0.p8" e1="DrugDDI.d343.s0.e1" e2="DrugDDI.d343.s0.e2" interaction="false"/><pair id="DrugDDI.d343.s0.p9" e1="DrugDDI.d343.s0.e1" e2="DrugDDI.d343.s0.e3" interaction="false"/><pair id="DrugDDI.d343.s0.p10" e1="DrugDDI.d343.s0.e1" e2="DrugDDI.d343.s0.e4" interaction="false"/><pair id="DrugDDI.d343.s0.p11" e1="DrugDDI.d343.s0.e1" e2="DrugDDI.d343.s0.e5" interaction="false"/><pair id="DrugDDI.d343.s0.p12" e1="DrugDDI.d343.s0.e1" e2="DrugDDI.d343.s0.e6" interaction="false"/><pair id="DrugDDI.d343.s0.p13" e1="DrugDDI.d343.s0.e1" e2="DrugDDI.d343.s0.e7" interaction="false"/><pair id="DrugDDI.d343.s0.p14" e1="DrugDDI.d343.s0.e1" e2="DrugDDI.d343.s0.e8" interaction="false"/><pair id="DrugDDI.d343.s0.p15" e1="DrugDDI.d343.s0.e2" e2="DrugDDI.d343.s0.e3" interaction="false"/><pair id="DrugDDI.d343.s0.p16" e1="DrugDDI.d343.s0.e2" e2="DrugDDI.d343.s0.e4" interaction="false"/><pair id="DrugDDI.d343.s0.p17" e1="DrugDDI.d343.s0.e2" e2="DrugDDI.d343.s0.e5" interaction="false"/><pair id="DrugDDI.d343.s0.p18" e1="DrugDDI.d343.s0.e2" e2="DrugDDI.d343.s0.e6" interaction="false"/><pair id="DrugDDI.d343.s0.p19" e1="DrugDDI.d343.s0.e2" e2="DrugDDI.d343.s0.e7" interaction="false"/><pair id="DrugDDI.d343.s0.p20" e1="DrugDDI.d343.s0.e2" e2="DrugDDI.d343.s0.e8" interaction="false"/><pair id="DrugDDI.d343.s0.p21" e1="DrugDDI.d343.s0.e3" e2="DrugDDI.d343.s0.e4" interaction="false"/><pair id="DrugDDI.d343.s0.p22" e1="DrugDDI.d343.s0.e3" e2="DrugDDI.d343.s0.e5" interaction="true"/><pair id="DrugDDI.d343.s0.p23" e1="DrugDDI.d343.s0.e3" e2="DrugDDI.d343.s0.e6" interaction="false"/><pair id="DrugDDI.d343.s0.p24" e1="DrugDDI.d343.s0.e3" e2="DrugDDI.d343.s0.e7" interaction="true"/><pair id="DrugDDI.d343.s0.p25" e1="DrugDDI.d343.s0.e3" e2="DrugDDI.d343.s0.e8" interaction="false"/><pair id="DrugDDI.d343.s0.p26" e1="DrugDDI.d343.s0.e4" e2="DrugDDI.d343.s0.e5" interaction="false"/><pair id="DrugDDI.d343.s0.p27" e1="DrugDDI.d343.s0.e4" e2="DrugDDI.d343.s0.e6" interaction="false"/><pair id="DrugDDI.d343.s0.p28" e1="DrugDDI.d343.s0.e4" e2="DrugDDI.d343.s0.e7" interaction="false"/><pair id="DrugDDI.d343.s0.p29" e1="DrugDDI.d343.s0.e4" e2="DrugDDI.d343.s0.e8" interaction="false"/><pair id="DrugDDI.d343.s0.p30" e1="DrugDDI.d343.s0.e5" e2="DrugDDI.d343.s0.e6" interaction="false"/><pair id="DrugDDI.d343.s0.p31" e1="DrugDDI.d343.s0.e5" e2="DrugDDI.d343.s0.e7" interaction="false"/><pair id="DrugDDI.d343.s0.p32" e1="DrugDDI.d343.s0.e5" e2="DrugDDI.d343.s0.e8" interaction="false"/><pair id="DrugDDI.d343.s0.p33" e1="DrugDDI.d343.s0.e6" e2="DrugDDI.d343.s0.e7" interaction="false"/><pair id="DrugDDI.d343.s0.p34" e1="DrugDDI.d343.s0.e6" e2="DrugDDI.d343.s0.e8" interaction="false"/><pair id="DrugDDI.d343.s0.p35" e1="DrugDDI.d343.s0.e7" e2="DrugDDI.d343.s0.e8" interaction="false"/></sentence><sentence id="DrugDDI.d343.s1" origId="s1" text="Substances that inhibit the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase imatinib concentrations."><entity id="DrugDDI.d343.s1.e0" origId="s1.p27" charOffset="28-43" type="drug" text="cytochrome P450"/><entity id="DrugDDI.d343.s1.e1" origId="s1.p29" charOffset="55-61" type="drug" text="CYP3A4"/><entity id="DrugDDI.d343.s1.e2" origId="s1.p37" charOffset="109-117" type="drug" text="imatinib"/><pair id="DrugDDI.d343.s1.p0" e1="DrugDDI.d343.s1.e0" e2="DrugDDI.d343.s1.e1" interaction="false"/><pair id="DrugDDI.d343.s1.p1" e1="DrugDDI.d343.s1.e0" e2="DrugDDI.d343.s1.e2" interaction="false"/><pair id="DrugDDI.d343.s1.p2" e1="DrugDDI.d343.s1.e1" e2="DrugDDI.d343.s1.e2" interaction="false"/></sentence><sentence id="DrugDDI.d343.s2" origId="s2" text="There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor)."><entity id="DrugDDI.d343.s2.e0" origId="s2.p42" charOffset="47-55" type="drug" text="imatinib"/><entity id="DrugDDI.d343.s2.e1" origId="s2.p44" charOffset="61-68" type="drug" text="Gleevec"/><entity id="DrugDDI.d343.s2.e2" origId="s2.p47" charOffset="92-104" type="drug" text="ketoconazole"/><entity id="DrugDDI.d343.s2.e3" origId="s2.p49" charOffset="106-112" type="drug" text="CYP3A4"/><pair id="DrugDDI.d343.s2.p0" e1="DrugDDI.d343.s2.e0" e2="DrugDDI.d343.s2.e1" interaction="false"/><pair id="DrugDDI.d343.s2.p1" e1="DrugDDI.d343.s2.e0" e2="DrugDDI.d343.s2.e2" interaction="false"/><pair id="DrugDDI.d343.s2.p2" e1="DrugDDI.d343.s2.e0" e2="DrugDDI.d343.s2.e3" interaction="false"/><pair id="DrugDDI.d343.s2.p3" e1="DrugDDI.d343.s2.e1" e2="DrugDDI.d343.s2.e2" interaction="true"/><pair id="DrugDDI.d343.s2.p4" e1="DrugDDI.d343.s2.e1" e2="DrugDDI.d343.s2.e3" interaction="false"/><pair id="DrugDDI.d343.s2.p5" e1="DrugDDI.d343.s2.e2" e2="DrugDDI.d343.s2.e3" interaction="false"/></sentence><sentence id="DrugDDI.d343.s3" origId="s3" text="Drugs that may decrease imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations."><entity id="DrugDDI.d343.s3.e0" origId="s3.p51" charOffset="0-5" type="drug" text="Drugs"/><entity id="DrugDDI.d343.s3.e1" origId="s3.p55" charOffset="24-32" type="drug" text="imatinib"/><entity id="DrugDDI.d343.s3.e2" origId="s3.p61" charOffset="88-94" type="drug" text="CYP3A4"/><entity id="DrugDDI.d343.s3.e3" origId="s3.p66" charOffset="141-149" type="drug" text="imatinib"/><pair id="DrugDDI.d343.s3.p0" e1="DrugDDI.d343.s3.e0" e2="DrugDDI.d343.s3.e1" interaction="false"/><pair id="DrugDDI.d343.s3.p1" e1="DrugDDI.d343.s3.e0" e2="DrugDDI.d343.s3.e2" interaction="false"/><pair id="DrugDDI.d343.s3.p2" e1="DrugDDI.d343.s3.e0" e2="DrugDDI.d343.s3.e3" interaction="false"/><pair id="DrugDDI.d343.s3.p3" e1="DrugDDI.d343.s3.e1" e2="DrugDDI.d343.s3.e2" interaction="false"/><pair id="DrugDDI.d343.s3.p4" e1="DrugDDI.d343.s3.e1" e2="DrugDDI.d343.s3.e3" interaction="false"/><pair id="DrugDDI.d343.s3.p5" e1="DrugDDI.d343.s3.e2" e2="DrugDDI.d343.s3.e3" interaction="false"/></sentence><sentence id="DrugDDI.d343.s4" origId="s4" text="Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital or St."><entity id="DrugDDI.d343.s4.e0" origId="s4.p67" charOffset="3-14" type="drug" text="medications"/><entity id="DrugDDI.d343.s4.e1" origId="s4.p70" charOffset="27-33" type="drug" text="CYP3A4"/><entity id="DrugDDI.d343.s4.e2" origId="s4.p73" charOffset="41-54" type="drug" text="dexamethasone"/><entity id="DrugDDI.d343.s4.e3" origId="s4.p74" charOffset="56-65" type="drug" text="phenytoin"/><entity id="DrugDDI.d343.s4.e4" origId="s4.p75" charOffset="67-80" type="drug" text="carbamazepine"/><entity id="DrugDDI.d343.s4.e5" origId="s4.p76" charOffset="82-90" type="drug" text="rifampin"/><entity id="DrugDDI.d343.s4.e6" origId="s4.p77" charOffset="92-105" type="drug" text="phenobarbital"/><pair id="DrugDDI.d343.s4.p0" e1="DrugDDI.d343.s4.e0" e2="DrugDDI.d343.s4.e1" interaction="false"/><pair id="DrugDDI.d343.s4.p1" e1="DrugDDI.d343.s4.e0" e2="DrugDDI.d343.s4.e2" interaction="false"/><pair id="DrugDDI.d343.s4.p2" e1="DrugDDI.d343.s4.e0" e2="DrugDDI.d343.s4.e3" interaction="false"/><pair id="DrugDDI.d343.s4.p3" e1="DrugDDI.d343.s4.e0" e2="DrugDDI.d343.s4.e4" interaction="false"/><pair id="DrugDDI.d343.s4.p4" e1="DrugDDI.d343.s4.e0" e2="DrugDDI.d343.s4.e5" interaction="false"/><pair id="DrugDDI.d343.s4.p5" e1="DrugDDI.d343.s4.e0" e2="DrugDDI.d343.s4.e6" interaction="false"/><pair id="DrugDDI.d343.s4.p6" e1="DrugDDI.d343.s4.e1" e2="DrugDDI.d343.s4.e2" interaction="false"/><pair id="DrugDDI.d343.s4.p7" e1="DrugDDI.d343.s4.e1" e2="DrugDDI.d343.s4.e3" interaction="false"/><pair id="DrugDDI.d343.s4.p8" e1="DrugDDI.d343.s4.e1" e2="DrugDDI.d343.s4.e4" interaction="false"/><pair id="DrugDDI.d343.s4.p9" e1="DrugDDI.d343.s4.e1" e2="DrugDDI.d343.s4.e5" interaction="false"/><pair id="DrugDDI.d343.s4.p10" e1="DrugDDI.d343.s4.e1" e2="DrugDDI.d343.s4.e6" interaction="false"/><pair id="DrugDDI.d343.s4.p11" e1="DrugDDI.d343.s4.e2" e2="DrugDDI.d343.s4.e3" interaction="false"/><pair id="DrugDDI.d343.s4.p12" e1="DrugDDI.d343.s4.e2" e2="DrugDDI.d343.s4.e4" interaction="false"/><pair id="DrugDDI.d343.s4.p13" e1="DrugDDI.d343.s4.e2" e2="DrugDDI.d343.s4.e5" interaction="false"/><pair id="DrugDDI.d343.s4.p14" e1="DrugDDI.d343.s4.e2" e2="DrugDDI.d343.s4.e6" interaction="false"/><pair id="DrugDDI.d343.s4.p15" e1="DrugDDI.d343.s4.e3" e2="DrugDDI.d343.s4.e4" interaction="false"/><pair id="DrugDDI.d343.s4.p16" e1="DrugDDI.d343.s4.e3" e2="DrugDDI.d343.s4.e5" interaction="false"/><pair id="DrugDDI.d343.s4.p17" e1="DrugDDI.d343.s4.e3" e2="DrugDDI.d343.s4.e6" interaction="false"/><pair id="DrugDDI.d343.s4.p18" e1="DrugDDI.d343.s4.e4" e2="DrugDDI.d343.s4.e5" interaction="false"/><pair id="DrugDDI.d343.s4.p19" e1="DrugDDI.d343.s4.e4" e2="DrugDDI.d343.s4.e6" interaction="false"/><pair id="DrugDDI.d343.s4.p20" e1="DrugDDI.d343.s4.e5" e2="DrugDDI.d343.s4.e6" interaction="false"/></sentence><sentence id="DrugDDI.d343.s5" origId="s5" text="Johns Wort) may significantly reduce exposure to Gleevec."><entity id="DrugDDI.d343.s5.e0" origId="s5.p88" charOffset="49-56" type="drug" text="Gleevec"/></sentence><sentence id="DrugDDI.d343.s6" origId="s6" text="Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8)."><entity id="DrugDDI.d343.s6.e0" origId="s6.p92" charOffset="58-66" type="drug" text="rifampin"/><entity id="DrugDDI.d343.s6.e1" origId="s6.p95" charOffset="96-103" type="drug" text="Gleevec"/><entity id="DrugDDI.d343.s6.e2" origId="s6.p96" charOffset="115-122" type="drug" text="Gleevec"/><pair id="DrugDDI.d343.s6.p0" e1="DrugDDI.d343.s6.e0" e2="DrugDDI.d343.s6.e1" interaction="true"/><pair id="DrugDDI.d343.s6.p1" e1="DrugDDI.d343.s6.e0" e2="DrugDDI.d343.s6.e2" interaction="false"/><pair id="DrugDDI.d343.s6.p2" e1="DrugDDI.d343.s6.e1" e2="DrugDDI.d343.s6.e2" interaction="false"/></sentence><sentence id="DrugDDI.d343.s7" origId="s7" text="In patients where rifampin or other CYP3A4 inducers are indicated, alternative therapeutic agents with less enzyme induction potential should be considered."><entity id="DrugDDI.d343.s7.e0" origId="s7.p107" charOffset="18-26" type="drug" text="rifampin"/><entity id="DrugDDI.d343.s7.e1" origId="s7.p109" charOffset="36-42" type="drug" text="CYP3A4"/><entity id="DrugDDI.d343.s7.e2" origId="s7.p113" charOffset="79-97" type="drug" text="therapeutic agents"/><pair id="DrugDDI.d343.s7.p0" e1="DrugDDI.d343.s7.e0" e2="DrugDDI.d343.s7.e1" interaction="false"/><pair id="DrugDDI.d343.s7.p1" e1="DrugDDI.d343.s7.e0" e2="DrugDDI.d343.s7.e2" interaction="false"/><pair id="DrugDDI.d343.s7.p2" e1="DrugDDI.d343.s7.e1" e2="DrugDDI.d343.s7.e2" interaction="false"/></sentence><sentence id="DrugDDI.d343.s8" origId="s8" text="Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec."><entity id="DrugDDI.d343.s8.e0" origId="s8.p118" charOffset="0-5" type="drug" text="Drugs"/><entity id="DrugDDI.d343.s8.e1" origId="s8.p124" charOffset="58-65" type="drug" text="Gleevec"/><entity id="DrugDDI.d343.s8.e2" origId="s8.p129" charOffset="109-120" type="drug" text="simvastatin"/><entity id="DrugDDI.d343.s8.e3" origId="s8.p131" charOffset="122-128" type="drug" text="CYP3A4"/><entity id="DrugDDI.d343.s8.e4" origId="s8.p139" charOffset="203-209" type="drug" text="CYP3A4"/><entity id="DrugDDI.d343.s8.e5" origId="s8.p140" charOffset="213-220" type="drug" text="Gleevec"/><pair id="DrugDDI.d343.s8.p0" e1="DrugDDI.d343.s8.e0" e2="DrugDDI.d343.s8.e1" interaction="false"/><pair id="DrugDDI.d343.s8.p1" e1="DrugDDI.d343.s8.e0" e2="DrugDDI.d343.s8.e2" interaction="false"/><pair id="DrugDDI.d343.s8.p2" e1="DrugDDI.d343.s8.e0" e2="DrugDDI.d343.s8.e3" interaction="false"/><pair id="DrugDDI.d343.s8.p3" e1="DrugDDI.d343.s8.e0" e2="DrugDDI.d343.s8.e4" interaction="false"/><pair id="DrugDDI.d343.s8.p4" e1="DrugDDI.d343.s8.e0" e2="DrugDDI.d343.s8.e5" interaction="false"/><pair id="DrugDDI.d343.s8.p5" e1="DrugDDI.d343.s8.e1" e2="DrugDDI.d343.s8.e2" interaction="true"/><pair id="DrugDDI.d343.s8.p6" e1="DrugDDI.d343.s8.e1" e2="DrugDDI.d343.s8.e3" interaction="false"/><pair id="DrugDDI.d343.s8.p7" e1="DrugDDI.d343.s8.e1" e2="DrugDDI.d343.s8.e4" interaction="false"/><pair id="DrugDDI.d343.s8.p8" e1="DrugDDI.d343.s8.e1" e2="DrugDDI.d343.s8.e5" interaction="false"/><pair id="DrugDDI.d343.s8.p9" e1="DrugDDI.d343.s8.e2" e2="DrugDDI.d343.s8.e3" interaction="false"/><pair id="DrugDDI.d343.s8.p10" e1="DrugDDI.d343.s8.e2" e2="DrugDDI.d343.s8.e4" interaction="false"/><pair id="DrugDDI.d343.s8.p11" e1="DrugDDI.d343.s8.e2" e2="DrugDDI.d343.s8.e5" interaction="false"/><pair id="DrugDDI.d343.s8.p12" e1="DrugDDI.d343.s8.e3" e2="DrugDDI.d343.s8.e4" interaction="false"/><pair id="DrugDDI.d343.s8.p13" e1="DrugDDI.d343.s8.e3" e2="DrugDDI.d343.s8.e5" interaction="false"/><pair id="DrugDDI.d343.s8.p14" e1="DrugDDI.d343.s8.e4" e2="DrugDDI.d343.s8.e5" interaction="false"/></sentence><sentence id="DrugDDI.d343.s9" origId="s9" text="Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide)."><entity id="DrugDDI.d343.s9.e0" origId="s9.p145" charOffset="53-60" type="drug" text="Gleevec"/><entity id="DrugDDI.d343.s9.e1" origId="s9.p146" charOffset="66-72" type="drug" text="CYP3A4"/><entity id="DrugDDI.d343.s9.e2" origId="s9.p152" charOffset="129-141" type="drug" text="cyclosporine"/><entity id="DrugDDI.d343.s9.e3" origId="s9.p154" charOffset="145-153" type="drug" text="pimozide"/><pair id="DrugDDI.d343.s9.p0" e1="DrugDDI.d343.s9.e0" e2="DrugDDI.d343.s9.e1" interaction="false"/><pair id="DrugDDI.d343.s9.p1" e1="DrugDDI.d343.s9.e0" e2="DrugDDI.d343.s9.e2" interaction="true"/><pair id="DrugDDI.d343.s9.p2" e1="DrugDDI.d343.s9.e0" e2="DrugDDI.d343.s9.e3" interaction="false"/><pair id="DrugDDI.d343.s9.p3" e1="DrugDDI.d343.s9.e1" e2="DrugDDI.d343.s9.e2" interaction="false"/><pair id="DrugDDI.d343.s9.p4" e1="DrugDDI.d343.s9.e1" e2="DrugDDI.d343.s9.e3" interaction="false"/><pair id="DrugDDI.d343.s9.p5" e1="DrugDDI.d343.s9.e2" e2="DrugDDI.d343.s9.e3" interaction="false"/></sentence><sentence id="DrugDDI.d343.s10" origId="s10" text="Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.)."><entity id="DrugDDI.d343.s10.e0" origId="s10.p156" charOffset="0-7" type="drug" text="Gleevec"/><entity id="DrugDDI.d343.s10.e1" origId="s10.p160" charOffset="70-75" type="drug" text="drugs"/><entity id="DrugDDI.d343.s10.e2" origId="s10.p163" charOffset="92-107" type="drug" text="benzodiazepines"/><entity id="DrugDDI.d343.s10.e3" origId="s10.p164" charOffset="125-149" type="drug" text="calcium channel blockers"/><entity id="DrugDDI.d343.s10.e4" origId="s10.p165" charOffset="159-187" type="drug" text="HMG-CoA reductase inhibitors"/><pair id="DrugDDI.d343.s10.p0" e1="DrugDDI.d343.s10.e0" e2="DrugDDI.d343.s10.e1" interaction="true"/><pair id="DrugDDI.d343.s10.p1" e1="DrugDDI.d343.s10.e0" e2="DrugDDI.d343.s10.e2" interaction="false"/><pair id="DrugDDI.d343.s10.p2" e1="DrugDDI.d343.s10.e0" e2="DrugDDI.d343.s10.e3" interaction="true"/><pair id="DrugDDI.d343.s10.p3" e1="DrugDDI.d343.s10.e0" e2="DrugDDI.d343.s10.e4" interaction="false"/><pair id="DrugDDI.d343.s10.p4" e1="DrugDDI.d343.s10.e1" e2="DrugDDI.d343.s10.e2" interaction="false"/><pair id="DrugDDI.d343.s10.p5" e1="DrugDDI.d343.s10.e1" e2="DrugDDI.d343.s10.e3" interaction="false"/><pair id="DrugDDI.d343.s10.p6" e1="DrugDDI.d343.s10.e1" e2="DrugDDI.d343.s10.e4" interaction="false"/><pair id="DrugDDI.d343.s10.p7" e1="DrugDDI.d343.s10.e2" e2="DrugDDI.d343.s10.e3" interaction="false"/><pair id="DrugDDI.d343.s10.p8" e1="DrugDDI.d343.s10.e2" e2="DrugDDI.d343.s10.e4" interaction="false"/><pair id="DrugDDI.d343.s10.p9" e1="DrugDDI.d343.s10.e3" e2="DrugDDI.d343.s10.e4" interaction="false"/></sentence><sentence id="DrugDDI.d343.s11" origId="s11" text="Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin."><entity id="DrugDDI.d343.s11.e0" origId="s11.p169" charOffset="8-16" type="drug" text="warfarin"/><entity id="DrugDDI.d343.s11.e1" origId="s11.p172" charOffset="35-41" type="drug" text="CYP2C9"/><entity id="DrugDDI.d343.s11.e2" origId="s11.p174" charOffset="46-52" type="drug" text="CYP3A4"/><entity id="DrugDDI.d343.s11.e3" origId="s11.p183" charOffset="139-146" type="drug" text="heparin"/><pair id="DrugDDI.d343.s11.p0" e1="DrugDDI.d343.s11.e0" e2="DrugDDI.d343.s11.e1" interaction="false"/><pair id="DrugDDI.d343.s11.p1" e1="DrugDDI.d343.s11.e0" e2="DrugDDI.d343.s11.e2" interaction="false"/><pair id="DrugDDI.d343.s11.p2" e1="DrugDDI.d343.s11.e0" e2="DrugDDI.d343.s11.e3" interaction="false"/><pair id="DrugDDI.d343.s11.p3" e1="DrugDDI.d343.s11.e1" e2="DrugDDI.d343.s11.e2" interaction="false"/><pair id="DrugDDI.d343.s11.p4" e1="DrugDDI.d343.s11.e1" e2="DrugDDI.d343.s11.e3" interaction="false"/><pair id="DrugDDI.d343.s11.p5" e1="DrugDDI.d343.s11.e2" e2="DrugDDI.d343.s11.e3" interaction="false"/></sentence><sentence id="DrugDDI.d343.s12" origId="s12" text="in vitro, Gleevec inhibits the cytochrome P450 isoenzyme CYP2D6 activity at similar concentrations that affect CYP3A4 activity."><entity id="DrugDDI.d343.s12.e0" origId="s12.p184" charOffset="10-17" type="drug" text="Gleevec"/><entity id="DrugDDI.d343.s12.e1" origId="s12.p186" charOffset="31-64" type="drug" text="cytochrome P450 isoenzyme CYP2D6"/><entity id="DrugDDI.d343.s12.e2" origId="s12.p190" charOffset="111-117" type="drug" text="CYP3A4"/><pair id="DrugDDI.d343.s12.p0" e1="DrugDDI.d343.s12.e0" e2="DrugDDI.d343.s12.e1" interaction="true"/><pair id="DrugDDI.d343.s12.p1" e1="DrugDDI.d343.s12.e0" e2="DrugDDI.d343.s12.e2" interaction="false"/><pair id="DrugDDI.d343.s12.p2" e1="DrugDDI.d343.s12.e1" e2="DrugDDI.d343.s12.e2" interaction="false"/></sentence><sentence id="DrugDDI.d343.s13" origId="s13" text="Systemic exposure to substrates of CYP2D6 is expected to be increased when coadministered with Gleevec."><entity id="DrugDDI.d343.s13.e0" origId="s13.p193" charOffset="35-41" type="drug" text="CYP2D6"/><entity id="DrugDDI.d343.s13.e1" origId="s13.p201" charOffset="95-102" type="drug" text="Gleevec"/><pair id="DrugDDI.d343.s13.p0" e1="DrugDDI.d343.s13.e0" e2="DrugDDI.d343.s13.e1" interaction="false"/></sentence><sentence id="DrugDDI.d343.s14" origId="s14" text="No specific studies have been performed and caution is recommended."/><sentence id="DrugDDI.d343.s15" origId="s15" text="in vitro, Gleevec inhibits acetaminophen O-glucuronidation (Ki value of 58.5 ?M) at therapeutic levels."><entity id="DrugDDI.d343.s15.e0" origId="s15.p210" charOffset="10-17" type="drug" text="Gleevec"/><entity id="DrugDDI.d343.s15.e1" origId="s15.p212" charOffset="27-40" type="drug" text="acetaminophen"/><pair id="DrugDDI.d343.s15.p0" e1="DrugDDI.d343.s15.e0" e2="DrugDDI.d343.s15.e1" interaction="true"/></sentence><sentence id="DrugDDI.d343.s16" origId="s16" text="Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec."><entity id="DrugDDI.d343.s16.e0" origId="s16.p219" charOffset="21-34" type="drug" text="acetaminophen"/><entity id="DrugDDI.d343.s16.e1" origId="s16.p227" charOffset="88-95" type="drug" text="Gleevec"/><pair id="DrugDDI.d343.s16.p0" e1="DrugDDI.d343.s16.e0" e2="DrugDDI.d343.s16.e1" interaction="true"/></sentence><sentence id="DrugDDI.d343.s17" origId="s17" text="No specific studies in humans have been performed and caution is recommended."/><sentence id="DrugDDI.d343.s18" origId="s18" text="?"/></document>